Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.56 |
| ▸ | CDK1 | P06493 | 4/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.56 |
| ▸ | CDK9 | P50750 | 3/20 | 0.56 |
| ▸ | CDK7 | P50613 | 2/20 | 0.56 |
| ▸ | CCNH | P51946 | 2/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.56 |
| ▸ | BMPR2 | Q13873 | 10/20 | 0.55 |
| ▸ | JAK3 | P52333 | 4/20 | 0.54 |
| ▸ | JAK1 | P23458 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622441 | 0.79 | IKBKB (0.59) | CDK2CDK1CCNT1CCNB1CCNA2 | |
| SCHEMBL3005199 | 0.77 | CDK9 (0.61) | CDK2CDK1CCNT1CCNB1CCNA2 | |
| SCHEMBL3621478 | 0.76 | CDK2 (0.54) | CDK2CDK1CCNT1CCNB1CCNA2 | |
| SCHEMBL3622052 | 0.76 | CDK2 (0.54) | CDK2CDK1CCNT1CCNB1CCNA2 | |
| SCHEMBL3610580 | 0.76 | CDK9 (0.81) | CDK2CDK1CCNT1CCNB1CCNA2 | |
| SCHEMBL16564535 | 0.76 | PTK2 (0.60) | CDK2CDK1CCNT1CCNB1CDK9 | |
| SCHEMBL3623248 | 0.75 | SYK (0.63) | CDK2CDK1CCNT1CCNB1CCNA2 | |
| SCHEMBL3620405 | 0.75 | CDK1 (0.55) | CDK2CDK1CCNT1CCNB1CCNA2 | |
| SCHEMBL3620313 | 0.75 | CDK1 (0.55) | CDK2CDK1CCNT1CCNB1CCNA2 | |
| SCHEMBL3613897 | 0.74 | CDK1 (0.57) | CDK2CDK1CCNT1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF | 2011-09-15 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | CDK2 4/4885CDK1 10/4885CCNT1 34/4885 |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK4, CDK6, CDKN1A | CDK2 6/4885CDK1 10/4885CCNT1 25/4885 |
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CDK2 3078/4885CDK1 3769/4885CCNT1 3196/4885 |
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | CDK2 4/4885CDK1 10/4885CCNT1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.